Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment

Neurol Sci. 2003 Oct;24(3):207-8. doi: 10.1007/s10072-003-0133-z.


This study analyzed the macrostructure and microstructure of sleep in 12 parkinsonian patients under basal conditions (T0) and during 1-night treatment (T1) with a new formulation of apomorphine. This new formulation consisted in a microemulsion of apomorphine administered by the transdermal route, able to provide a constant release of the drug over several hours (APO-TD). Sleep analysis at T1 compared with T0 revealed a 16% increment of total sleep time, a 12% increment of sleep efficiency, a 16% increment of stage 3 and 4 non-REM sleep, a 15% reduction of periodic limb movements index, a 22% reduction of arousal index, and a 23% reduction of cycling alternating patterns/non-REM. We conclude that APO-TD may be able to reduce nocturnal anomalous movements, akinesia, and rigidity in Parkinson's disease, and may reduce the disturbed sleep typical of Parkinson's disease.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Cutaneous
  • Aged
  • Antiparkinson Agents / therapeutic use*
  • Apomorphine / therapeutic use*
  • Arousal / drug effects
  • Chromatography, High Pressure Liquid
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Levodopa / therapeutic use
  • Middle Aged
  • Movement / drug effects
  • Parkinson Disease / blood
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Polysomnography / methods
  • Restless Legs Syndrome / drug therapy
  • Sleep / drug effects*
  • Sleep Apnea Syndromes / drug therapy


  • Antiparkinson Agents
  • Delayed-Action Preparations
  • Levodopa
  • Apomorphine